VIYASH NSE filing

Viyash Scientific Q2 FY27 Earnings Call Transcript Released

The RealCase readHigh impact Positive

Viyash Scientific released its Q2 FY27 earnings call transcript. The company reported H1 FY27 revenue of ₹1,934 crores (up 17.8%) and Q2 FY27 revenue of ₹988 crores (up 16.2%). Net debt reduced to ₹26 crores. The acquisition of BioForLife is being integrated. Management projects over 50% PAT growth for FY27.

Why it matters

The announcement relates to the detailed financial performance of the company for the quarter and half-year, along with strategic updates on acquisitions and future growth plans, which are material information for investors.

The market read

The company reported strong financial results with double-digit growth in revenue and significant increase in profit after tax. Key strategic initiatives like acquisitions and new product development are progressing well, and debt levels have been substantially reduced, indicating a positive outlook.

Viyash Scientific Limited (formerly Sequent Scientific Limited) has released the transcript of its Earnings Call held on November 14, 2026, for the Q2 FY27 Financial Results. The transcript is available on the company's website.

During the call, management highlighted strong performance for Q2 FY27, marking the fifth consecutive quarter of double-digit growth with strong margins and reducing debt. For the first half of FY27, consolidated revenue stood at ₹1,934 crores, a 17.8% year-on-year increase, with pre-ESOP EBITDA at ₹412 crores (up 30%) and Profit After Tax at ₹164 crores (up 50%). For Q2 FY27 specifically, revenue was ₹988 crores (up 16.2% year-on-year), pre-ESOP EBITDA was ₹208 crores, and Profit After Tax was ₹85 crores (up 16%). The net debt has significantly reduced to ₹26 crores.

The company is integrating the acquisition of BioForLife, effective October 1, 2026, with consolidation starting from Q3 FY27. Strategic initiatives in animal health include geo-extension of BioForLife products, expansion into Vietnam, and development of new companion animal products targeting launches up to 2035, with significant R&D investment and a dedicated companion animal facility planned for commissioning by Q1 FY28. Human health business is also focusing on complex products and has commissioned a new oncology finished doses R&D center.

Management expressed confidence in continued strong performance for H2 FY27, projecting PAT growth of over 50% for the full year. Discussions also covered the US business performance, capex guidance for the next three years (estimated at ₹140-150 crores for the current year, and ₹150-170 crores for the next two to three years), and the trajectory of the API business.

Filing to action

What to do with a filing like this

Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.

View original filing